Eloralintide
Investigational Long-Acting GLP-1 Receptor Agonist
01
Overview
Eloralintide is an investigational long-acting GLP-1 receptor agonist in the incretin therapy class, engineered for sustained appetite suppression and metabolic regulation. As a next-generation candidate, it is designed to offer extended receptor engagement and prolonged satiety signaling with a favorable pharmacokinetic profile suitable for less frequent dosing.
02
Mechanism of Action
Eloralintide mimics endogenous GLP-1, binding GLP-1 receptors on pancreatic beta cells to stimulate glucose-dependent insulin secretion while suppressing glucagon. Central GLP-1 receptor activation in the hypothalamus and brainstem reduces appetite and increases satiety. Structural modifications are designed to resist DPP-4 degradation and extend circulating half-life through albumin-binding conjugation.
03
Research Highlights
Preclinical pharmacokinetic profiling confirms extended receptor occupancy versus native GLP-1
Comparative GLP-1 receptor binding studies demonstrate sustained agonist activity
Animal metabolism models show reduced food intake and body weight consistent with GLP-1 class effects
04
Dosage
Administration & Timing
Subcutaneous (SC) injection into abdominal or gluteal subcutaneous tissue, once weekly or daily depending on research protocol. Investigational amylin analog; timing independent of meals.
Dosage Guidelines
Cycle Length
4–12 weeks; research is early-stage.
05
Reconstitution
Solvent
Bacteriostatic Water (0.9% benzyl alcohol)
Volume
Per research formulation
Concentration
Per protocol
Storage
Refrigerate at 2–8 °C; protect from light. Discard 30 days after reconstitution.
Notes
Eloralintide is a next-generation amylin analog in early clinical development. Limited published data — approach research dosing conservatively.
Research Reference Only
Dosage and reconstitution values reflect commonly cited ranges from published research literature and are presented for educational and research reference only. This is not medical advice or a dosing recommendation. HEXAGEN does not endorse human use of any compound. Always consult a qualified healthcare professional.
Research Disclaimer
Eloralintide is for educational and research purposes only. Not intended as medical advice. Consult a qualified healthcare professional before making any health-related decisions.
Related Compounds
View All
Eloralintide Knowledge Graph
Explore how Eloralintide connects to mechanisms, research goals, related compounds, research stacks, and scientific references. Drag nodes, zoom, and filter by type.
No nodes match the active filters.
Eloralintide — Common Research Questions
What is Eloralintide?
Eloralintide is an investigational long-acting GLP-1 receptor agonist in the incretin therapy class, engineered for sustained appetite suppression and metabolic regulation. As a next-generation candid... Eloralintide belongs to the Weight Loss research category and is studied for its investigational long-acting glp-1 receptor agonist.
How does Eloralintide work?
Eloralintide mimics endogenous GLP-1, binding GLP-1 receptors on pancreatic beta cells to stimulate glucose-dependent insulin secretion while suppressing glucagon. Central GLP-1 receptor activation in the hypothalamus and brainstem reduces appetite and increases satiety. Structural modifications are designed to resist DPP-4 degradation and extend circulating half-life through albumin-binding conjugation.
What are the key research benefits of Eloralintide?
Sustained GLP-1 receptor activation for prolonged satiety. Designed for extended half-life and reduced dosing frequency. Appetite suppression and caloric intake reduction. Glycemic control via glucose-dependent insulin stimulation. Gastric emptying modulation for extended meal satiety. Potential cardiometabolic benefit profile consistent with GLP-1 class.
What is the molecular structure of Eloralintide?
Eloralintide is a research compound in the Weight Loss category. Detailed molecular structure data is being compiled. Refer to primary literature for structural analysis.
What does the research say about Eloralintide?
Preclinical pharmacokinetic profiling confirms extended receptor occupancy versus native GLP-1 Comparative GLP-1 receptor binding studies demonstrate sustained agonist activity Animal metabolism models show reduced food intake and body weight consistent with GLP-1 class effects These findings are based on preclinical and clinical research. Eloralintide is a research compound and these studies do not constitute medical advice.
Is Eloralintide FDA approved?
No. Eloralintide is not FDA-approved for any indication. It is a research chemical studied in preclinical and early clinical research. These compounds are not approved for human therapeutic use and should only be studied in appropriate research settings.
What category does Eloralintide belong to?
Eloralintide belongs to the Weight Loss category, which focuses on compounds studied for their roles in metabolic regulation, growth hormone signaling, and targeted adipose tissue reduction. You can explore more compounds in this category on the Weight Loss pillar page.
Related Articles
Tesamorelin: Clinical Data for Visceral Fat Reduction
Phase III trial data showing 15-18% visceral fat reduction and the FDA approval rationale for Egrifta®.
AOD-9604: Lipolysis Without Growth Effects
How AOD-9604's C-terminus fragment of HGH stimulates lipolysis without the growth-promoting effects of full-length HGH.
CJC-1295 + Ipamorelin: Synergistic GH Secretagogue Research
Examining the complementary mechanisms of CJC-1295 (GHRH analogue) and Ipamorelin (ghrelin mimetic) in research settings.
Scientific References
Preclinical pharmacokinetic profiling confirms extended receptor occupancy versus native GLP-1
Comparative GLP-1 receptor binding studies demonstrate sustained agonist activity
Animal metabolism models show reduced food intake and body weight consistent with GLP-1 class effects